Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AQST
- Price
- 3.25
- Stock movement down
- -0.11 (-3.27%)
- Company name
- Aquestive Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 396.51M
- Ent value
- 435.12M
- Price/Sales
- 9.14
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -27.90%
- 1 year return (CAGR)
- 1.25%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AQST does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 9.14 |
| Price to Book | - |
| EV to Sales | 10.03 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 122.00M |
| EPS (TTM) | -0.62 |
| FCF per share (TTM) | -0.46 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 43.40M |
| Gross profit (TTM) | 26.16M |
| Operating income (TTM) | -55.79M |
| Net income (TTM) | -68.98M |
| EPS (TTM) | -0.62 |
| EPS (1y forward) | -0.45 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 60.28% |
| Operating margin (TTM) | -128.56% |
| Profit margin (TTM) | -158.95% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 129.06M |
| Net receivables | 11.80M |
| Total current assets | 151.67M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 52.59M |
| Total assets | 163.56M |
| Accounts payable | 10.87M |
| Short/Current long term debt | 128.86M |
| Total current liabilities | 25.57M |
| Total liabilities | 167.67M |
| Shareholder's equity | -4.11M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -50.45M |
| Capital expenditures (TTM) | 492.00K |
| Free cash flow (TTM) | -50.94M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -42.17% |
| Return on Invested Capital | -2446.93% |
| Cash Return on Invested Capital | -1807.17% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 3.36 |
| Daily high | 3.42 |
| Daily low | 3.24 |
| Daily Volume | 3.13M |
| All-time high | 18.96 |
| 1y analyst estimate | 10.56 |
| Beta | 1.58 |
| EPS (TTM) | -0.62 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AQST | S&P500 | |
| Current price drop from All-time high | -82.86% | -0.89% |
| Highest price drop | -88.40% | -19.00% |
| Date of highest drop | 14 May 2025 | 8 Apr 2025 |
| Avg drop from high | -77.66% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
396.51M
Marketcap category
Small-cap
Description
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
Employees
142
Website
Investor relations
-
SEC filings
CEO
Keith J. Kendall
Country
USA
City
Warren
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page